Drug Trial Radar · NCT00856973
Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Last checked: Nov 20, 2026Latest source record: Jun 17, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
486
Actual
Start
May 2009
Primary completion
Jul 2011
Study completion Jul 2011
Sponsor
- Lead sponsor
- Sumitomo Pharma America, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 6, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multi center, randomized study to evaluate the efficacy and safety of eszopiclone compared to placebo in children (6-11 years of age, inclusive) and adolescents (12-17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.
Conditions
- Insomnia
- Attention Deficit Hyperactivity Disorder
Interventions
eszopicloneDrug
1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years
eszopicloneDrug
2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years
PlaceboDrug
1 tablet per day for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to the End of the Double- Blind Treatment Period (Week 12) in Polysomnography (PSG) Defined Latency to Persistent Sleep (LPS).Time frame: Baseline (Day 0) to Week 12
Locations
73 sites in 1 country. Site status is shown where the registry gives one.
Sleep Disorders Center of Alabama
Birmingham, Alabama
Dothan Behavioral Medicine Clinic
Dothan, Alabama
Metropolitan Neuro Behavioral Institute
Chandler, Arizona
PsyPharma Clinical Research
Phoenix, Arizona
REM Medical Clinical Research
Tucson, Arizona
Paul E. Wylie
Little Rock, Arkansas
AV Institute, Inc.
Carson, California
Clinical Innovations, Inc.
Costa Mesa, California
Avastra Clinical Trials
Fountain Valley, California
Behavioral Research Specialists, LLC
Glendale, California
Pacific Institute for Medical Research Inc
Los Angeles, California
Excell Research, Inc.
Oceanside, California
North County Clinical Research (NCCR)
Oceanside, California
Pacific Clinical Research Medical Group
Orange, California
SDS Clinical Trials
Orange, California
California Clinical Trials Medical Group
Paramount, California
Clinical Innovations, Inc.
Riverside, California
Artemis Institute for Clinical Research
San Diego, California
Clinical Innovations, Inc.
San Diego, California
Neuropsychiatric Research Center of Orange County
Santa Ana, California
Clinical Innovations, Inc.
Santa Ana, California
Elite Clinical Trials
Wildomar, California
Delta Waves, INC
Colorado Springs, Colorado
Sarkis Clinical Trials
Gainesville, Florida
MD Clinical
Hallandale, Florida
Florida Clinical Research Center LLC
Maitland, Florida
Florida Institute for Clinical Research, LLC
Orlando, Florida
SomnoMedics, LLC
Tampa, Florida
Pediatric Epilepsy and Neurology Specialists
Tampa, Florida
Neuro Trials Research, Inc.
Atlanta, Georgia
Sleep Disorders Center of Georgia
Atlanta, Georgia
Mountain West Clinical Trials
Eagle, Idaho
Alexian Brothers Center for Psychiatric Research
Hoffman Estates, Illinois
AMR Baber Research Inc.
Naperville, Illinois
American Medical Research, Inc.
Oak Brook, Illinois
Davis Clinic
Indianapolis, Indiana
Goldpoint Clinical Research
Indianapolis, Indiana
Psychiatric Associates
Overland Park, Kansas
Pedia Research LLC
Owensboro, Kentucky
Louisiana Research Associates, Inc.
New Orleans, Louisiana
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.